|
Patent landscape, scope, and claims: |
Executive summary
US Patent 7,767,225 claims oral hard-gelatin capsules containing 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone/pirfenidone free base naming used in the specification), with specified excipient loadings and, critically, an AUC-increasing binder excipient effect versus capsules with no excipients. The enforceable scope centers on: (1) 5–30% binder/excipient by weight with specific binder identities (povidone and/or microcrystalline cellulose), (2) wet-granulated manufacture using binder + filler + disintegrator, (3) quantitative povidone and component ranges, and (4) a downstream method-of-use for fibrotic and cytokine-mediated conditions. Patent validity and infringement risk for generic or “authorized” substitutes is driven less by the active ingredient and more by whether the accused product matches the claimed capsule composition ranges and manufacturing form and achieves the claimed AUC uplift benchmarks.
What does US patent 7,767,225 claim for 5-methyl-1-phenyl-2-(1H)-pyridone capsules?
Core claim construction themes
Claim 1 is the anchor. It is framed as a capsule comprising a pharmaceutical formulation of 5-methyl-1-phenyl-2-(1H)-pyridone with:
- 70–95 wt% active
- 5–30 wt% “pharmaceutically acceptable excipients”
- excipients “comprise an effective amount of binder to increase the AUC of pirfenidone upon oral administration, as compared to a capsule comprising no excipients.”
Key takeaways for scope:
- Composition + functional PK effect are both required. The binder is not merely present; it must be present in an “effective amount” that increases AUC versus a “no excipients” comparison capsule.
- The claim is not limited to povidone or microcrystalline cellulose in claim 1. Those limitations appear in dependent claims (3, 5, 8, and later quantitative povidone ranges).
- The claim is directed to a capsule dosage form (not tablets, powders, or sustained-release units unless also claimed by broader independent claim language).
How dependent claims narrow the estate
The dependent claims progressively lock in identity and ranges:
- Claim 2: excipients further comprise disintegrators, fillers, lubricants.
- Claim 3: binder comprises microcrystalline cellulose, povidone, or a combination.
- Claim 4: quantifies component classes:
- disintegrator 2–10 wt%
- binder 2–30 wt%
- filler 2–30 wt%
- lubricant 0.3–0.8 wt%
- Claims 5–6, 10, 15: povidone-specific floors and ranges:
- binder comprises povidone (claim 5)
- povidone at least ~1 wt% (claim 6)
- wet-granulation context still depends on claim 9/20
- povidone 1–4 wt% (claim 10)
- povidone at least ~1.85 wt% (claim 15)
- Claims 7, 18–19: dose and binder identity/range:
- total active 100–400 mg (claim 7)
- microcrystalline cellulose binder (claim 8)
- binder total 2–30 wt% (claim 19) and combinations.
- Claims 9 and 20: manufacturing limitation: wet-granulated mixture.
- Claims 12–14: AUC effect thresholds, expressed as minimum % increases:
- at least 30% (claim 12)
- at least 40% (claim 13)
- at least 60% (claim 14)
Each is “as compared to a capsule comprising no excipients.”
- Claim 11 (method-of-use): “treating a fibrotic condition or inhibiting actions of cytokines” by administering the claimed capsule.
How broad is claim coverage: formulation composition vs AUC functional limitation?
Is the AUC limitation likely a strict infringement requirement?
Claims 1 and 12–14 use “an effective amount of binder to increase AUC … compared to a capsule comprising no excipients,” and then specify minimum % increases (30/40/60%). This is typically treated as a limitation that must be satisfied by the accused product’s in vivo performance (or by equivalently measured/validated AUC outcomes).
Practical breadth:
- A generic product that matches all composition and manufacturing parameters but does not deliver the claimed AUC uplift could fall outside literal infringement of claims 1 and certainly outside claims 12–14.
- Conversely, an accused product with lower AUC would reduce infringement probability even if composition overlaps, assuming “effective amount” is interpreted as tied to the claimed PK effect.
Scope center of gravity
The strongest infringement case tends to be where a defendant:
- uses capsules
- contains ~100–400 mg active per capsule (claim 7)
- includes povidone and/or microcrystalline cellulose binder
- uses wet granulation
- includes the component ranges (disintegrator 2–10%, lubricant 0.3–0.8%, binder 2–30%, filler 2–30%, povidone 1–4% or ≥1.85% depending on which claims are asserted)
- shows AUC increase consistent with dependent claims.
Which excipient identities and ranges define the patent’s “infringement perimeter”?
Binder identity and loading
- Binder choices: microcrystalline cellulose and/or povidone (claim 3)
- Binder loading range: 2–30 wt% (claims 4 and 19)
- Povidone floors/ranges:
- ≥1 wt% (claim 6)
- 1–4 wt% (claim 10)
- ≥1.85 wt% (claim 15)
Disintegrator, filler, and lubricant constraints
- Disintegrator: 2–10 wt% (claim 4)
- Filler: 2–30 wt% (claim 4)
- Lubricant: 0.3–0.8 wt% (claim 4)
These appear in combination, particularly in the wet-granulation set (claim 20 and claim 9).
Wet-granulated mixture requirement
- Claim 9: wet-granulated mixture comprising active + binder (AUC-effective) + filler + disintegrator
- Claim 20: recites a full tuple:
- excipients include lubricant + filler + disintegrator
- binder = microcrystalline cellulose + povidone
- povidone = 1–4 wt%
- total binder = 2–30 wt%
- wet-granulated mixture includes active + binder + filler + disintegrator
This manufacturing requirement is a major scope limiter. If an accused product uses a different granulation method (dry granulation or direct compression), the wet-granulated limitation can be a design-around for those dependent claims, though claim 1 still lacks the wet-granulation limitation.
What therapeutic and indication coverage does US 7,767,225 include?
Method-of-use claim scope
Claim 11: administering the claimed capsule for:
- fibrotic conditions, or
- inhibiting cytokine actions.
This is broad in therapeutic language. It is not restricted to a specific disease name in the claim text you provided. In enforcement, that generally becomes a question of labeling and how clinicians reasonably use the accused drug.
Enforcement profile
Method-of-use claims can be enforced via:
- marketing and labeling alignment
- direct physician/healthcare provider actions
- “induced infringement” theories tied to promotional materials
However, actual litigation posture will depend on the FDA label and the drug’s marketed indication set. The claim text you provided is sufficient to establish broad indication capture, but it does not identify specific listed indications.
What is the likely patent landscape around pirfenidone AUC-enhancing capsule excipients?
Landscape structure
For pirfenidone (a pyridone-derived antifibrotic-type agent), patents commonly cluster into:
- Active pharmaceutical ingredient (API) composition and polymorph/crystal form patents.
- Solid-state formulation patents: excipient selection, granulation method (wet granulation), binder systems, tablet/capsule form factors, and dissolution profiles.
- PK/bioavailability patents: AUC-boosting excipient systems, particle size and manufacturing process tied to systemic exposure.
- Methods of use for fibrotic/cytokine-mediated conditions.
US 7,767,225 fits cluster (2) and (3) with a functional AUC limitation.
How this claim set typically impacts generics
For generic entry, the key is whether the applicant can demonstrate bioequivalence under an FDA bioequivalence study while also potentially avoiding the claimed excipient/method-of-use territory:
- If they pursue a capsule that uses different binders, different granulation, or different component ranges, they can often reduce infringement likelihood.
- If they match the claim’s excipient ranges and binder identity, they still face an AUC-effect question, which can be difficult to “design around” without changing formulation.
When does US 7,767,225 lose exclusivity and what launch timing does that imply?
No accurate exclusivity timeline can be produced from the claim text alone. Patent term depends on:
- filing date
- patent grant date
- any PTA
- any terminal disclaimer
- continuation claims and prosecution history
- whether any regulatory exclusivity is relevant (and for which listed product)
Because the required bibliographic data is not included in your prompt, a timing or expiration assertion would be incomplete.
What generic entry risks exist if a competitor wants a capsule with “similar” excipients?
High-risk design targets to match (or to avoid matching)
For a capsule generic to fall outside the most enforceable dependent claims, designers usually try to avoid one of the following buckets:
- Binder identity mismatch
- Avoid povidone and microcrystalline cellulose combinations as defined in claims 3, 8, and 20.
- Povidone quantity mismatch
- Avoid the specific povidone range and floors: ≥1 wt%, 1–4 wt%, ≥1.85 wt%.
- Component range mismatch
- Avoid the disintegrator/filler/lubricant ranges (2–10%, 2–30%, 0.3–0.8%).
- Manufacturing mismatch
- Avoid wet granulation (claim 9 and claim 20).
- AUC effect mismatch
- Avoid demonstrating an AUC increase meeting the threshold (30/40/60%) against the “no excipients” comparator used in the patent framing.
AUC threshold creates an evidence-driven risk
Even if composition overlaps, the defendant can challenge whether its AUC uplift matches the claimed comparator and magnitude. In litigation, the bottleneck becomes expert interpretation of what “compared to a capsule comprising no excipients” means operationally and what test conditions map to that comparison.
How does US 7,767,225 compare with a “typical” solid oral formulation patent?
Notable differences
Most excipient patents rely on structural limitations (what excipients, in what amounts). This one also includes:
- a performance-based limitation (AUC increase)
- explicit percentage AUC uplift thresholds in dependent claims
That pushes the estate toward pharmacokinetic performance evidence and increases the importance of:
- PK study design
- comparator formulation definition
- assay and sampling schedule alignment
- whether the test product is truly “no excipients” comparand, not merely “lower excipient” comparand
Which jurisdictions beyond the US are implicated?
The claim set provided is US-only by nature of the patent number. No PCT/EP/WO or other jurisdiction data is present in your prompt, so cross-jurisdiction mapping cannot be completed from the provided information.
What is the likely Orange Book status of the underlying product?
Orange Book status requires FDA listing data (application number, listed drug, patents and exclusivities). The prompt includes neither the drug’s NDA/BLA identifiers nor the Orange Book listing for US 7,767,225. No status determination can be made solely from the claim text you provided.
How strong is the patent estate for litigation: enforceability vs design-around?
Strength factors
- Clear, objective numerical ranges (binder, disintegrator, filler, lubricant, povidone).
- Manufacturing limitation exists in multiple dependent claims (wet granulation).
- Functional limitation is tied to AUC with explicit thresholds (30/40/60%) in claims 12–14.
Design-around vectors
- Replace binder system with a non-claimed binder identity (different polymer/binder class).
- Shift granulation method away from wet granulation.
- Adjust excipient loading outside specified ranges.
- Target PK outcome not meeting the claimed AUC uplift thresholds.
Method-of-use breadth
Claim 11 is broad enough to cover many fibrotic and cytokine-mediated uses. That can increase potential enforcement reach, but practical success still depends on label and evidence of induced use.
Key claim-to-risk mapping table (US 7,767,225)
| Claim |
What must be present |
Main enforcement lever |
Common design-around |
| 1 |
Capsule with 70–95% active; 5–30% excipients; binder “effective amount” increases AUC vs “no excipients” |
Functional AUC effect + composition |
Change binder class/amount or avoid achieving AUC uplift |
| 2 |
Adds disintegrator, filler, lubricant in excipients |
Component presence |
Remove/replace component classes |
| 3 |
Binder = microcrystalline cellulose and/or povidone |
Binder identity |
Use different binder |
| 4 |
Disintegrator 2–10%, binder 2–30%, filler 2–30%, lubricant 0.3–0.8% |
Numerical ranges |
Adjust loadings outside ranges |
| 5–6 |
Binder includes povidone; povidone ≥1 wt% |
Povidone inclusion |
Reduce below threshold or use non-povidone binder |
| 7 |
Active 100–400 mg per capsule |
Dose amount |
Different per-capsule dose |
| 9 |
Wet-granulated mixture includes active + binder + filler + disintegrator |
Manufacturing limitation |
Switch to dry granulation/direct compression |
| 10 |
Povidone 1–4 wt% |
Povidone window |
Move outside 1–4 wt% |
| 11 |
Method-of-use for fibrotic/cytokine-mediated conditions |
Indication coverage |
Avoid indicated use and marketing alignment |
| 12–14 |
AUC increase ≥30/40/60% |
PK threshold |
Formulate to avoid meeting thresholds |
| 15–16 |
Povidone ≥1.85 wt%; binder may include MCC |
Tight povidone floor |
Lower below ~1.85 wt% |
| 19–20 |
Binder total 2–30 wt% + wet-granulated + binder = MCC + povidone; povidone 1–4 wt% |
Combined tuple |
Break the tuple (binder identity, povidone %, granulation) |
Key Takeaways
- US 7,767,225 is primarily an oral capsule formulation patent built around binder-mediated AUC enhancement for 5-methyl-1-phenyl-2-(1H)-pyridone.
- The enforceable scope is concentrated in numerical excipient ranges, specific binder identities (povidone and/or microcrystalline cellulose), and wet-granulated manufacture in dependent claims.
- A major litigation fault line is the AUC functional limitation and, in dependent claims, the 30/40/60% AUC increase thresholds versus a “no excipients” comparator.
- Generic/copycat risk is highest where an accused capsule matches both composition/method-of-manufacture and demonstrates the claimed AUC uplift.
FAQs
-
Does US 7,767,225 protect tablets or only capsules?
The claim set you provided is explicitly directed to a capsule dosage form.
-
Can a product infringe claim 1 without using povidone or microcrystalline cellulose?
Claim 1 requires a “binder” with AUC-increasing effectiveness but does not, in the text provided, restrict binder identity; dependent claims do.
-
What is the strictest quantitative limitation in the claims you provided?
The most explicit are the component ranges (e.g., lubricant 0.3–0.8 wt%) and the AUC uplift thresholds (30%, 40%, 60%) that must be met for claims 12–14.
-
How much does wet granulation matter to infringement risk?
Wet-granulated manufacture is expressly required in dependent claims 9 and 20, making it a key design-around for those claim targets.
-
Is the indication coverage limited to a named fibrotic disease?
Claim 11 is drafted at the level of fibrotic conditions and cytokine-mediated disorders, without limiting the claim text to a specific disease name.
References
- United States Patent No. 7,767,225 (claims as provided in user prompt).
More… ↓
⤷ Start Trial
|
